Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025

Risk scores designed for pulmonary arterial hypertension (Group I of the World Health Organisation classification for pulmonary hypertension) do not adequately account for the unique pathophysiology seen in patients whose pulmonary hypertension arises from underlying lung disease (Group III of the World Health Organisation (WHO) classification). This is the rationale behind a retrospective study of […]

Tool identifies degree of 1-year mortality risk in patients with pulmonary hypertension due to underlying lung disease, Healio, August 26, 2025 Read Post »

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH)

Cereno Scientific announced on August 26, 2025 that the US Food and Drug Administration (FDA) has granted Fast Track designation to CS1, its lead drug candidate for treating pulmonary arterial hypertension (PAH). This designation accelerates development and regulatory review for treatments addressing serious conditions with high unmet medical need. In a Phase IIa trial, it

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH) Read Post »

The causal effect of gut microbiome on pulmonary artery hypertension based on a two-sample Mendelian randomization study, Nutrition & Metabolism, July 29, 2025

Previous studies have shown that pulmonary arterial hypertension patients have different gut bacteria compositions, with lower diversity and fewer anti-inflammatory bacteria that produce beneficial short-chain fatty acids. Could the gut-lung connection contribute to pulmonary arterial hypertension development through enhanced nerve communication and altered bacterial metabolites like trimethylamine-N-oxide? In this two-sample Mendelian randomization study, recently published

The causal effect of gut microbiome on pulmonary artery hypertension based on a two-sample Mendelian randomization study, Nutrition & Metabolism, July 29, 2025 Read Post »

Real-life use of quality of life questionnaires in pulmonary arterial hypertension in Spain, European Journal of Cardiovascular Nursing, July 7, 2025

Despite strong recommendations to assess quality of life in pulmonary arterial hypertension patients from the World Symposia on Pulmonary Hypertension (WSPH) in 2018 and 2024, and from the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint pulmonary hypertension guidelines, this evaluation remains rarely implemented in clinical practice. This cross-sectional study of

Real-life use of quality of life questionnaires in pulmonary arterial hypertension in Spain, European Journal of Cardiovascular Nursing, July 7, 2025 Read Post »

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025

A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025 Read Post »

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025

The Research: Evidence on the predictive ability of risk assessment models for event-free survival (EFS) in patients with pulmonary arterial hypertension is scarce, say the authors of a recent study published on Pulmonary Circulation. The aim of the study was to evaluate how well three different risk assessment models predict event-free survival. The study included 411

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025 Read Post »

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025

Current targeted medications for pulmonary arterial hypertension can help symptoms but have limited long-term effectiveness and often cause significant side effects and high costs. Percutaneous pulmonary artery denervation is a realtively new interventional procedure that selectively destroys sympathetic nerves to restore nerve and hormone balance in patients who don’t respond well to standard medications – see

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025 Read Post »

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025

A recent study titled “Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes” analysed two common health factors in people with pulmonary hypertension: inflammation and body weight. Inflammation is associated with all types of pulmonary hypertension. In the study inflammation was measured by a blood test called C-reactive protein (CRP), and body

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025 Read Post »

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025

Researchers have found two specific genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers that could help doctors detect idiopathic pulmonary arterial hypertension (IPAH) earlier and possibly guide treatment. This study, published in Scientific Reports on July 12, 2025, focused on genes linked to ferroptosis, an iron-dependent type of cell

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025 Read Post »

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025

In pulmonary arterial hypertension (PAH) lung blood vessel cells grow excessively, increasing vascular resistance and ultimately leading to right heart failure. While researchers understand many molecular mechanisms behind pulmonary arterial hypertension, effective treatments remain limited. Programmed cell death (PCD) plays a crucial role in the pathogenesis of various diseases, including cancer, chronic conditions, cardiovascular disorders,

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025 Read Post »

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025

A review published on Current Opinion in Pulmonary Medicine on July 8, 2025 examines recent negative clinical trials in pulmonary arterial hypertension (PAH) research, emphasizing the valuable insights these studies provide despite their unsuccessful outcomes. The article reviews several recent negative trials testing various therapeutic approaches in pulmonary arterial hypertension, including tocilizumab (an anti-inflammatory drug),

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025

A large US registry study of 1,671 patients with pulmonary arterial hypertension (PAH) over 4607 person-years of follow up found that lung transplant referrals are occurring far too infrequently and too late in the disease course. Despite professional society recommendations for early referral, only 12% of patients were referred for transplantation over the study period.

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025 Read Post »

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025

Researchers at the University of California, Los Angeles (UCLA), have achieved a breakthrough by successfully growing miniature lungs from stem cells that include functioning blood vessel networks for the first time. Published in Cell, this advancement represents a significant step forward because previous lung organoids lacked the essential vascular systems needed for proper lung function.

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025 Read Post »

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025

Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes. Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025 Read Post »

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025

Pulmonary arterial hypertension has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. Based on data from major pulmonary arterial hypertension clinical trials the authors of a recent study published in Therapeutic Advances in Respiratory Disease have found that: These sex-based differences, say the authors, highlight

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025 Read Post »

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025

Existing treatments pulmonary arterial hypertension (PAH) widen blood vessels, can help relieve symptoms and extend life, but cannot cure the disease or repair the damaged vessels. The field is now moving toward treatments that could actually modify the underlying disease process, based on promising laboratory research that’s being tested in patients. Two important breakthroughs include

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025 Read Post »

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension

Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension Read Post »

Enrollment completed in ongoing PROSERA Phase 3 study for seralutinib in pulmonary arterial hypertension

Gossamer Bio, Inc. today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III pulmonary arterial hypertension patients. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. See also our previous article about the PROSERA study at this link

Enrollment completed in ongoing PROSERA Phase 3 study for seralutinib in pulmonary arterial hypertension Read Post »

TRANSLATE »
Scroll to Top